A prior-authorization form has room for about one number, and these trials supply it: scalp coverage measured at week 24 [7]. Work out what that number asks of the patient it is applied to. Enrollees had lost about 84% of their scalp hair on average, which leaves roughly 16% coverage at the start [3][11]. The 80% mark therefore sits about 64 percentage points above where the average participant began, close to 2.7 points of scalp per week across the 24 weeks, if the average is the patient in front of you [12]. In someone who arrived with most of their scalp hair gone, that is a large move, and it is the reason this reads as a coverage question rather than a journal curiosity [4].
The people who have to act on it are the pharmacy and benefits teams who already handle upadacitinib for rheumatoid arthritis and other inflammatory conditions [2]. The molecule is already stocked and the dose is once daily [1][5]. What sits between this data and a treated patient is the criteria document: who qualifies, and what happens at review.
Here is what a committee tells itself. Half the patients responded, so authorise a 24-week trial of therapy and re-review. Here is what the published account actually carries. One threshold, at one time point, with the investigators themselves saying that longer treatment and follow-up are needed to know how durable the regrowth is and how the benefit weighs against the risk [10]. The summary reports that both doses beat placebo substantially [16] but gives no placebo response rate and no adverse-event figures [15], and it does not separate the 15mg result from the 30mg one [18]. Degree and speed of regrowth varied between patients [9], which is the polite way of saying the average conceals the cases you will argue about.
Adherence to a once-daily pill is the easiest thing in this file to measure and the least informative. The measure with content is coverage held at the date you set for re-review, and nobody has published that yet [10].
So write the stopping rule before you write the starting rule. Cross two questions: did this patient clear the threshold at week 24, and can you say what you will pay for in week 25. The cell that breaks policies is the partial responder, the person at 60% coverage with real regrowth and no durability evidence behind him, and roughly half the dosed patients in these trials did not clear 80% [13]. That case gets decided either in your criteria now or in an appeal later.
